The government’s reevaluation of approved and listed drugs is in full swing. The stated purpose is to filter out ineffective drugs and provide coverage to better ones. As this is very necessary for the public, it is the government's responsibility to fulfill this task.

The reevaluation is being conducted omnidirectionally by the Ministry of Food and Drug Safety (MFDS), which conducts the approval review, and the Health Insurance Review and Assessment Service (HIRA), which conducts the reimbursement evaluations. MFDS is in charge of conducting the bioequivalence reevaluations for generic drugs and clinical reevaluations for drugs with little evidence literature.

HIRA is conducting a reev